Starter Assets in Pipeline
| Mechanism | Indication/ Mkt | Discovery | Pre-Clinical | Phase I | Phase II | Phase III | Launch | |
|---|---|---|---|---|---|---|---|---|
| VA106483 | V2 Agonist & Backups | BPH / Nocturia >$1bn potential |
 |
|
|
 |
||
| VA111913 | V1a Antagonist & Backups | Dysmenorrhoea $multi bn |
|
|
|
|||
| VA118020 | KLK1 Inhibitor | Respiratory Disease $bns | |
|
||||
| KKI | Kallikrein Inhibitor Platform | Inflammatory Diseases $bns | |
|||||
| FAP | FAP Platform | Oncology $bns | |
VA106483 is a Vasopressin agonist, currently being developed for the treatment of nocturia, this product is currently in Phase 2 stage of clinical trials.
VA111913 is a vasopressin antagonist, about to enter human trials (in 2008) for the treatment of dysmenorrhoea, a common condition in women of childbearing age. VA111913 acts directly on the uterus, and may represent the first of a new type of therapy for this debilitating condition.
VA118020 is a tissue kallikrein inhibitor that is in preclinical development for use in respiratory disorders. It is a first-in-class oral therapy.
KKI is a platform of compounds, the lead of which are entering pre-clinical development in 2008. The compounds work by inhibiting Kallikreins, in a very specific way - to reduce inflammation. These compounds are being developed for a variety of inflammatory diseases.
FAP is a platform of Fibroblast Activation Protein Inhibitors in lead discovery, these compounds have potential application in several Oncological & Fibrotic diseases.